Company intelligence / Profile preview

AlloMek Therapeutics

Woodbridge, Connecticut, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

AlloMek's lead asset, CIP-137401—a proprietary macrocyclic MEK 1/2 inhibitor—demonstrated robust preclinical proof of concept in neurofibromatosis type 1 and LMNA cardiomyopathy models, showing strong potency, safety, and pharmacokinetic profile. IND-enabling toxicology studies were completed and it received orphan designation for NF1, but no clinical trials were started before acquisition by Pasithea Therapeutics.

Therapeutic areas: OncologyCardiovascularRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Connecticut InnovationsFundación Andreas Marcio

Beyond the preview

Go deeper on AlloMek Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlloMek Therapeutics.

Explore the full profile